Temodar Dosage
Generic name: Temozolomide 5mg
Dosage forms: capsule, injection, powder, lyophilized, for solution
Drug class: Alkylating agents
Medically reviewed by Drugs.com. Last updated on Sep 14, 2023.
2.1 Monitoring to Inform Dosage and Administration
Prior to dosing, withhold TEMODAR until patients have an absolute neutrophil count (ANC) of 1.5 x 109/L or greater and a platelet count of 100 x 109/L or greater.
For concomitant radiotherapy, obtain a complete blood count prior to initiation of treatment and weekly during treatment.
For the 28-day treatment cycles, obtain a complete blood count prior to treatment on Day 1 and on Day 22 of each cycle. Perform complete blood counts weekly until recovery if the ANC falls below 1.5 x 109/L and the platelet count falls below 100 x 109/L.
For concomitant use with focal radiotherapy, obtain a complete blood count weekly and as clinically indicated.
Recommended Dosage and Dosage Modifications for Newly Diagnosed Glioblastoma
Administer TEMODAR either orally or intravenously once daily for 42 to 49 consecutive days during the concomitant use phase with focal radiotherapy, and then once daily on Days 1 to 5 of each 28-day cycle for 6 cycles during the maintenance use phase.
Provide Pneumocystis pneumonia (PCP) prophylaxis during the concomitant use phase and continue in patients who develop lymphopenia until resolution to Grade 1 or less.
Concomitant Use Phase:
The recommended dosage of TEMODAR is 75 mg/m2 either orally or intravenously once daily for 42 to 49 days in combination with focal radiotherapy. Focal radiotherapy includes the tumor bed or resection site with a 2 to 3 cm margin.
Other administration schedules have been used.
Obtain a complete blood count weekly. The recommended dosage modifications due to adverse reactions during concomitant use phase are provided in Table 1.
Adverse Reaction | Interruption | Discontinuation |
---|---|---|
Absolute Neutrophil Count | Withhold TEMODAR if ANC is greater than or equal to 0.5 × 109/L and less than 1.5 × 109/L. | Discontinue TEMODAR if ANC is less than 0.5 × 109/L. |
Resume TEMODAR at the same dose when ANC is greater than or equal to 1.5 × 109/L. | ||
Platelet Count | Withhold TEMODAR if platelet count is greater than or equal to 10 × 109/L and less than 100 × 109/L. | Discontinue TEMODAR if platelet count is less than 10 × 109/L. |
Resume TEMODAR at the same dose when platelet count is greater than or equal to 100 × 109/L. | ||
Non-hematological Adverse Reaction (except for alopecia, nausea, vomiting) | Withhold TEMODAR if Grade 2 adverse reaction occurs. | Discontinue TEMODAR if Grade 3 or 4 adverse reaction occurs. |
Resume TEMODAR at the same dose when resolution to Grade 1 or less. |
Single Agent Maintenance Use Phase:
Beginning 4 weeks after concomitant use phase completion, administer TEMODAR either orally or intravenously once daily on Days 1 to 5 of each 28-day cycle for 6 cycles. The recommended dosage of TEMODAR in the maintenance use phase is:
- Cycle 1: 150 mg/m2 per day on days 1 to 5.
- Cycles 2 to 6: May increase to 200 mg/m2 per day on days 1 to 5 before starting Cycle 2 if no dosage interruptions or discontinuations are required (Table 1). If the dose is not escalated at the onset of Cycle 2, do not increase the dose for Cycles 3 to 6.
Obtain a complete blood count on Day 22 and then weekly until the ANC is above 1.5 × 109/L and the platelet count is above 100 × 109/L. Do not start the next cycle until the ANC and platelet count exceed these levels.
The recommended dosage modifications due to adverse reactions during the maintenance use phase are provided in Table 2.
If TEMODAR is withheld, reduce the dose for the next cycle by 50 mg/m2 per day. Permanently discontinue TEMODAR in patients who are unable to tolerate a dose of 100 mg/m2 per day.
Adverse Reactions | Interruption and Dose Reduction | Discontinuation |
---|---|---|
Absolute Neutrophil Count | Withhold TEMODAR if ANC less than 1 × 109/L. | Discontinue TEMODAR if unable to tolerate a dose of 100 mg/m2 per day. |
When ANC is above 1.5 × 109/L, resume TEMODAR at reduced dose for the next cycle. | ||
Platelet Count | Withhold TEMODAR if platelet less than 50 × 109/L. | Discontinue TEMODAR if unable to tolerate a dose of 100 mg/m2 per day. |
When platelet count is above 100 × 109/L, resume TEMODAR at reduced dose for the next cycle. | ||
Nonhematological Adverse Reactions (except for alopecia, nausea, vomiting) | Withhold TEMODAR if Grade 3 adverse reaction occurs. | Discontinue TEMODAR if recurrent Grade 3 adverse reaction occurs after dose reduction, if Grade 4 adverse reaction occurs, or if unable to tolerate a dose of 100 mg/m2 per day. |
When resolved to Grade 1 or less, resume TEMODAR at reduced dose for the next cycle. |
2.3 Recommended Dosage and Dosage Modifications for Anaplastic Astrocytoma
Adjuvant Treatment of Newly Diagnosed Anaplastic Astrocytoma
Beginning 4 weeks after the end of radiotherapy, administer TEMODAR orally in a single dose on days 1 to 5 of a 28-day cycle for 12 cycles. The recommended dosage of TEMODAR is:
- Cycle 1: 150 mg/m2 per day on days 1 to 5.
- Cycles 2 to 12: 200 mg/m2 per day on days 1 to 5 if patient experienced no or minimal toxicity in Cycle 1. If the dose was not escalated at the onset of Cycle 2, do not increase the dose during Cycles 3 to 6.
The recommended complete blood count testing and dosage modifications due to adverse reactions during adjuvant treatment are provided above and in Table 2.
Refractory Anaplastic Astrocytoma
The recommended initial dosage of TEMODAR is 150 mg/m2 once daily on Days 1 to 5 of each 28-day cycle. Increase the TEMODAR dose to 200 mg/m2 per day if the following conditions are met at the nadir and on Day 1 of the next cycle:
- ANC is greater than or equal to 1.5 × 109/L, and
- Platelet count is greater than or equal to 100 × 109/L.
Continue TEMODAR until disease progression or unacceptable toxicity.
Obtain a complete blood count on Day 22 and then weekly until the ANC is above 1.5 x 109/L and the platelet count is above 100 x 109/L. Do not start the next cycle until the ANC and platelet count exceed these levels.
If the ANC is less than 1 × 109/L or the platelet count is less than 50 × 109/L during any cycle, reduce the TEMODAR dose for the next cycle by 50 mg/m2 per day. Permanently discontinue TEMODAR in patients who are unable to tolerate a dose of 100 mg/m2 per day.
Preparation and Administration
TEMODAR is a hazardous drug. Follow applicable special handling and disposal procedures.1
TEMODAR capsules
Take TEMODAR at the same time each day. Administer TEMODAR consistently with respect to food (fasting vs. nonfasting). To reduce nausea and vomiting, take TEMODAR on an empty stomach or at bedtime and consider antiemetic therapy prior to and following TEMODAR administration.
Swallow TEMODAR capsules whole with water. Advise patients not to open, chew, or dissolve the contents of the capsules.
If capsules are accidentally opened or damaged, take precautions to avoid inhalation or contact with the skin or mucous membranes. In case of powder contact, wash the affected area with water immediately.
TEMODAR for injection
Bring the vial to room temperature prior to reconstitution with Sterile Water for Injection.
Reconstitute the vial with 41 mL of Sterile Water for Injection to yield a TEMODAR solution with a concentration of 2.5 mg/mL temozolomide. Reconstituted TEMODAR is a clear solution and essentially free of visible particles.
Gently swirl vial. Do not shake.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if particulate matter or discoloration is observed.
Do not further dilute the reconstituted solution.
Store reconstituted solution at room temperature (25°C [77°F]). Discard reconstituted solution if not used within 14 hours, including infusion time.
Withdraw up to 40 mL from each vial to make up the total dose and discard any unused portion. Transfer reconstituted solution from each vial into an empty 250 mL infusion bag.
Administer reconstituted solution using a pump over a period of 90 minutes. Administer TEMODAR by intravenous infusion only. Infusion over a shorter or longer period of time may result in suboptimal dosing. Flush the lines before and after each infusion. TEMODAR for injection may be administered in the same intravenous line with 0.9% Sodium Chloride injection only.
Because no data are available on the compatibility of TEMODAR for injection with other intravenous substances or additives, do not infuse other medications simultaneously through the same intravenous line.
More about Temodar (temozolomide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: alkylating agents
- En español
Patient resources
- Temodar drug information
- Temodar (Temozolomide Intravenous) (Advanced Reading)
- Temodar (Temozolomide Oral) (Advanced Reading)
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.